Marc Beer has been appointed the Chairman of the Board of LumeN XT, Inc. LumeNXT is a private company which develops proprietary surgical illumination products for minimally invasive surgeries. He has extensive development and commercialization experience in pharmaceuticals, biotechnology, diagnostics, and devices.
In a statement, Mr. Marc Beer said that he was proud to be working with dedicated team members. He works with highly successful group of engineers and surgeons who have been instrumental in the advancement of the surgical illumination field. He also highlighted how important the LumeN XT is in ensuring performance of safe surgeries. He finished by saying that he believes the importance of the LumeN XT platform will continue to grow as more minimally invasive surgeries are performed.
Surgeons who have used the targeted illumination have testified to the efficiency of the technology in enhancing precision, visualization, as well as flexibility during operations. In fact, it is more efficient that traditional techniques. LumeN XT brings a highly advanced illumination platform leveraged as a heat reduction to enhance surgical precision. It is also improves enhances visualization to increase safety during surgeries and improves low-cost disposable options.
According to the Co-Founder of LumeN XT, Paul Rhyne, Marc Beer has been highly successful in starting companies and guiding them throughout their growth. He also said that Mr. Beer’s experience in starting companies and helping them to rollout in a global scale will be highly valuable for his new company. He has led many startups along the path of profitability.
Currently, Mr. Beer serves as the Founder of Renovia, Inc., a women’s health startup. Prior to starting the startup, Beer was the Former Founding Chairman of Minerva Neurosciences Inc., a health company specialized in the development of treatment products for diseases related to the central nervous system. Minerva has been conducting several late-stage clinical trials and developing innovative therapeutic compounds for insomnia and mood disorders, schizophrenia, Parkinson’s disease, as well as major depressive disorders.
Prior to joining Minerva, Marc Beer held multiple leadership roles in the field of biopharmaceutical. In the roles, he was responsible for initiating various commercial launches to address rare disease on a global scale, Initial public offerings (IPOs), global growth, and many more. Some of the capacities Marc has held previously include Founding Chairman of the board of Good Start Genetics, Inc., Former CEO of ViaCell, Board of Directors of Erytech Pharma, Global Marketing Vice President at Genzyme, as well as multiple sales as well as marketing roles at Abbott Laboratories. Additionally, Marc Beer served as a member on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board and the Mass Life Science Board of the Commonwealth of Massachusetts. He attended Miami University where he graduated from with a Bachelor of Science in Business, an education background which prepared him immensely for the roles he held later in his career.